MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 52, Issue 4, 2008, Pages 388-402

  Boubaker, Ariane ^a,b   Delaloye, A Bischof ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

3 Iodobenzylguanidine; Child; Diagnosis; Neuroblastoma, diagnosis; Scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; DOPAMINE; IODINE 123; IODINE 131; LABETALOL;

BONE MARROW METASTASIS; BONE METASTASIS; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG INHIBITION; DRUG URINE LEVEL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; WHOLE BODY SCINTISCANNING;

3-IODOBENZYLGUANIDINE; CHILD; FOLLOW-UP STUDIES; HUMANS; NEUROBLASTOMA; RISK;

EID: 60549083512     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuebni CE. The Swiss childhood cancer registry: rationale, organisation and results for the years 2001-2005. Swiss Med Wkly 2007;137:502-9.
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20.
3. Hildebrandt T, Traunecker H. Neuroblastoma: a tumour with many faces. Curr Paediatr 2005;15:412-20.
4. Wood L, Lowis S. An update on neuroblastoma. Paediatr Child Health 2008;18:123-8.
5. Conte M, Parodi S, De Bernardi B, Milanaccic, C, Mazzocco K, Angelini P et al. Neuroblastoma in adolescents. The Italian experience. Cancer 2006;106:1409-17.
6. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
7. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-72.
8. London WB, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P et al. Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23:6459-65.
9. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M et al. Favourable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group study. J Clin Oncol 2005;23:6474-80.
10. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L et al. Hyperploidy plus nonamplified MYCN confers a favourable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;23:6466-73.
11. Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12-7.
12. Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC. Primary extra-adrenal pheochromocytoma positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med 1986;11:851-4. J Nucl Med 1998;38:679.
13. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998;39:679-88.
14. Olivier P, Colarinha P, Fettich J, Fischer S, Frökier J, Giammarile F et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003;30:B45-50.
15. Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine-131 uptake by pheochromocytoma and normal tissues. J Nucl Med 1989;30:481-9.
16. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.
17. Lebtahi Hadj-Djilani N, Lebtahi NE, Bischof Delaloye A, Laurini R, Beck D. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med 1995;22:322-9.
18. Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, de Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol 2000;35:153-5.
19. Geatti O, Shapiro B, Shulkin BL, Hutchinson R, Sisson JC. Gastrointestinal iodine 131-meta-iodobenzylguanidine activity. Am J Physiol Imaging 1988;3:188-91.
20. Bonnin F, Lumbroso J, Tenenbaum F, Hartmann O, Parmentier C. Refining interpretation of MIBG scans in children. J Nucl Med 1994;35:803-10.
21. Hadi M, Chen CC, Whatley M, Pacak K, Carrasquillo JA. Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma. J Nucl Med 2007;48:1077-83.
22. Chen W, Botvinick EH, Alavi A, Zhang Y, Yang S, Perini R et al. Age related decrease in cardiopulmonary adrenergic neuronal function in children as assessed by I-123 metaiodobenzylguanidine imaging. J Nucl Cardiol 2008;15:73-9.
23. 123I-metaiodobenzylguanidine accumulation in a urinoma and cortex of an obstructed kidney after surgical resection of an abdominal neuroblastoma. Pediatr Radiol 2008;38:118-21.
24. McGarvey CK, Applegate K, Lee ND, Sokol DK. False-positive metaiodobenzylguanidine scan for neuroblastoma in a child with ospoclonus-myoclonus syndrome treated with adrenocorticotropic hormone (ACTH). J Child Neurol 2006;21:606-10.
25. Granata C, Carlini C, Conte M, Claudiani F, Campus R, Rizzo A. False positive MIBG scan due to accessory spleen. Med Pediatr Oncol 2001;37:138-9.
26. Boubaker A, Bischof Delaloye A. Nuclear medicine procedures and neuroblastoma in childhood: their value in the diagnosis, staging and assessment of response to therapy. Q J Nucl Med 2003;47:31-40.
27. Howman-Giles R, Shaw PJ, Uren RF, Chung DKV. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2007;37:286-302.
28. Kaste SC, McCarville MB. Imaging pediatric abdominal tumors. Semin Roentgenol 2008;43:50-9.
29. McHugh K. Renal and adrenal tumours in children. Cancer Imaging 2007;7:41-51.
30. Gelfand MJ, Elgazzar AH, Kriss VM, Masters PR, Golsch GJ. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994;35:1753-7.
31. Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996;37:1464-8.
32. Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR 2008;190:1085-90.
33. 123I MIBG mapping with intraoperative gamma probe for recurrent neuroblastoma. Mol Imaging Biol 2008;10:19-23.
34. 123I-metaiodobenzylguanidine (MIBG) scan in a patient with angiomyolipoma; positive MIBG scan does not necessarily indicate the presence pf pheochromocytoma. Inter Med 2007;46:1717-21.
35. Jacobsson H, Hellström PM, Kogner P, Larsson SA. Different concentrations of I-123 MIBG and In-111 pentetreotide in the two main liver lobes in children: persisting regional functional differences after birth? Clin Nucl Med 2007;32:24-8.
36. Fenig E, Mishaeli M, Yerushalmi R, Sever SB, Ash S, Kornreich L et al. Treatment of neuroblastoma using the fused imaprig guided radiotherapy (FIGURA) system. Clin Nucl Med 2006;31:256-8.
37. Siegel MJ, Ishwaran H, Fletcher BD, Meyer JS, Hoffer FA, Jaramillo D et al. Staging of neuroblastoma at imaging: report of the Radiology Diagnostic Oncology Group. Radiology 2002;223:168-75.
38. Goo HW, Choi SH, Ghim T, Moon HM, Seo JJ. Whole-body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods. Pediatr Radiol 2005;35:766-73.
39. Cohen M, Siddiqui A. Importance of recognizing differences between bone marrow and bone cortex. Pediatr Radiol 2006;36:276.
40. Hahn K, Charron M, Shulkin BL. Role of MR imaging and iodine 123 MIBG scintigraphy in staging of pediatric neuroblastoma. Radiology 2003;227:908-9.
41. Lebtahi NE, Gudinchet F, Nenadov-Beck M, Beck D, Bischof Delaloye A. Evaluating bone marrow metastasis of neuroblastoma with iodine-123-MIBG scintigraphy and MRI. J Nucl Med 1997;38:1389-92.
42. Nuchtern JG. Perinatal neuroblastoma. Semin Pediatr Surg 2006;15:10-6.
43. Lukens JN. Neuroblastoma in the neonate. Semin Perinatol 1999;23:263-73.
44. Michalowski MB, Rubie H, Michon J, Montamat S, Bergeron C, Coze C et al.; Groupe Neuroblastome de la Société Française d'Oncologie Pédiatrique. [Neonatal localized neuroblastoma: 52 cases treated from 1990 to 1999]. Arch Pediatr 2004; 11:782-8.
45. Granata C, Fagnani AM, Gambini C, Boglino C, Bagnulo S, Cecchetto G et al. Features and outcome of neuroblastoma detected before birth. J Pediatr Surg 2000;35:88-91.
46. Papaioannou G, McHugh K. Neuroblastoma in childhood: review and radiological findings. Cancer Imaging 2005;5:116-27.
47. Meersman A, Wojciechowski M, Vaneerdeweg W, Jorens P, Michiels E, Ramet J. Acute retroperitoneal hemorrhage ans shock as presenting signs of neuroblastoma in an infant. Pediatr Emerg Care 2008;24:37-8.
48. Isaacs H Jr. Fetal and neonatal neuroblastoma: retrospective review of 271 cases. Fetal Pediatr Pathol 2007;26:177-84.
49. Sauvat F, Sarnacki S, Brisse H, Medioni J, Rubie H, Aigrain Y et al. Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer 2002; 94:2474-80.
50. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005;17:7-13.
51. Russell HV, Golding LA, Suell MN, Nuchtern JG, Strother DR. The role of bone marrow evaluation in the staging of patients with otherwise localized, low-risk neuroblastoma. Pediatr Blood Oncol 2005;45:916-9.
52. Simon T, Spitz R, Faldum A, Hero B, Berthold F. New definition of low-risk neuroblastoma using stage age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004;26:791-6.
53. Strenger V, Kerbl R, Dornbusch HJ, Ladenstein R, Ambros PF, Ambros IM et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer 2007;48:504-9.
54. Spitz R, Betts DR, Simon T, Boensch M, Oestreich J, Niggli FK et al. Favorable outcome of triploid neuroblastoma: a contribution to the special oncogenesis of neuroblastoma. Cancer Genet Cytogenet 2006;167:51-6.
55. Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL. Clinical significance of MYCN amplification and ploidy in favourable-stage neuroblastoma: a report from the Children's Oncology Group. J Clin Oncol 2008;26:913-8.
56. Sano H, Bonadio J, Gerbing RB, London WB, Matthay KK, Lukens JN et al. International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. EurJ Cancer 2006;42:1113-9.
57. Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. Cancer 2001;92:2699-708.
58. Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi W, Smith EI et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the Pediatric Oncology Group experience - A Pediatric Oncology Group study. J Clin Oncol 1998;16:2007-17.
59. 123I-MIBG-positive bone marrow involvement. Pediatr Blood Oncol 2006;46:264-5.
60. Levitt GA, Platt KA, De Byrne R, Sebire N, Owens CM. 4S neuroblastoma: the long-term outcome. Pediatr Blood Oncol 2004;43:120-5.
61. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter AG et al. Localized infant neuroblastoma often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008;26:1504-10.
62. Mora J, Cheung NKV, Chen L, Qin J, Gerald W. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Cancer 2001;91:435-42.
63. Escobar MA, Grosfeld JR, Powell RL, West KW, Scherer III LR, Fallon RJ et al. Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg 2006;41:377-81.
64. Mora J, Gerald WL, Qin J, Cheung NKV. Evolving significance of prognostic markers associated with treatment improvement in patients with stage IV neuroblastoma. Cancer 2002;94:2756-65.
65. Frappaz D, Bonneu A, Chauvot P, Edeline V, Giammarile F, Siles S et al. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. Med Pediatr Oncol 2000;34:237-41.
66. http://www.siopen-r-net.org/
67. Viprey VF, Corrias MV, Kagedal B, Oltra S, Swerts K, Vicha A et al. Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality insurance on behalf of SIOPEN-R-NET. Eur J Cancer 2007;43:341-50.
68. Messina JA, Cheng SC, Benjamin LF, Charron M, Shulkin B, To B et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865-74.
69. Kushner BH, Cheung NKV. Exploiting the MIBG-avidity of neuroblastoma for staging and treatment. Pediatr Blood Cancer 2006;47:863-4.
70. Frappaz D, Combaret V, Desuzinges C, Bouffet E, Bailly C, Favrot MC et al. Can MIBG scan replace the need for bone marrow assessment at diagnosis and reassessment in stage IV neuroblastoma? Bull Cancer 2004;91:253-64.
71. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group study. J Clin Oncol 2000;18:4067-76.
72. Hero B, Hunneman DH, Gahr M, Berthold F. Evaluation of catecholamines, mIBG scan, and bone marrow cytology as response marker in stage IV neuroblastoma. Med Pediatr Oncol 2001;36: 220-3.
73. Kushner BH, Yeh SDJ, Kramer K, Larson SM, Cheung NKV. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003;21:1082-6.
74. 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003;21:2486-91.
75. 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol 2004;22:3909-15.
76. 123I-mIBG in patients with stage IV neuroblastoma >1 year of age on high-risk treatment protocol: results of the German neuroblastoma trial NB97. Eur J Cancer 2008,doi:10.1016/ i.ejca.2008.03.013.
77. Minard V, Hartmann O, Peyroulet MC, Michon J, Coze C, Defachelle AS et al. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology. Br J Cancer 2000;83:973-9
78. Dubois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology and survival. J Pediatr Hematol Oncol 1999;21:181-9.
79. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbong RB et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol 2000;18:1260-8.
80. Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Reinhart T et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000;18:3604-13.
81. Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM et al. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict outcome in children with neuroblastoma? A Children's Oncology Group Study. Clin Cancer Res 2006;12:5693-7.
82. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
83. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-53.
84. Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008;358:2585-93.